

Factsheet

full title Personalised blueprint of intestinal health

programme Horizon Europe / HORIZON-HLTH-2022-STAYHLTH-02

contract number 101095470

abstract miGut-Health aims to develop a personalised blueprint of intestinal health to predict and prevent inflammatory bowel disease (IBD). The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management.

Taking on this mission, miGut-Health pursues the following strategic goals:

- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identifying actionable biomarkers, risk and health-promoting factors linked to health-to-disease transition in the general population, IBD high-risk persons, and as IBD patients.
- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.
- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free) and its impact on intestinal inflammation in IBD patients and high-risk individuals.
- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.
- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.
- To implement a patient-centred approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population, as well as tools for healthcare professionals.



**Funded by
the European Union**

Project funded by



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Federal Department of Economic Affairs,
Education and Research EAER
**State Secretariat for Education,
Research and Innovation SERI**

duration 48 months (01/01/2023 – 31/12/2026)

project funding € 7,537,493.75 (€ 7,126,243.75 funded by the European Union plus € 411,250.00 funded by the State Secretariat for Education, Research, and Innovation – SERI as a financial contribution to the Swiss partner)

partners Belgium

- The European Federation of Crohn's & Ulcerative Colitis Associations

Denmark

- Region Hovedstaden

Germany

- University Hospital Schleswig Holstein
 - Christian-Albrechts-University of Kiel (Affiliated entity)
- Medical Center Hamburg-Eppendorf (UKE)
- Eurice – European Research and Project Office GmbH
 - RISE - Research and Innovation Services (Affiliated entity, Croatia)

Israel

- Weizmann Institute of Science

Italy

- Università Cattolica del Sacro Cuore

Lithuania

- Lithuanian University of Health Sciences

Netherlands

- University Medical Center Groningen

Sweden

- Örebro University

Switzerland

- École Polytechnique Fédérale de Lausanne



**Funded by
the European Union**

Project funded by



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Federal Department of Economic Affairs,
Education and Research EAER
**State Secretariat for Education,
Research and Innovation SERI**

CONTACTS

- coordinator** Prof. Andre Franke
University Hospital Schleswig-Holstein
Email: a.franke@ikmb.uni-kiel.de
- co-coordinator** Prof. Jurgita Skieceviciene
Lithuanian University of Health Sciences
Email: jurgita.skieceviciene@ismuni.lt
- project manager** Antonija Zrno Culap
RISE – Research and Innovation Services
Email: a.zrno-culap@eurice.eu
- website** <https://www.migut-health.eu>
- social media** X: <https://twitter.com/miGutHealth>
LinkedIn: <https://twitter.com/miGutHealth>



Project funded by

